NDAINTRAVENOUSSOLUTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
4/8 — Partial
BENDAMUSTINE HYDROCHLORIDE (bendamustine hydrochloride) by Dr. Reddy's Laboratories is purine-like benzimidazole ring. Approved for chronic lymphocytic leukemia, non-hodgkin's lymphoma, small lymphocytic lymphoma. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bendamustine hydrochloride is a purine-like benzimidazole alkylating agent approved for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and small lymphocytic lymphoma. It forms interstrand DNA crosslinks through bifunctional covalent bonding, inducing cell death in both quiescent and dividing cells. The exact mechanism remains incompletely understood despite decades of clinical use.
Launch
Product entering market in July 2025 under moderate competitive pressure (30/100); early-stage team building expected for launch infrastructure.
Mechanism of Action
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways.…
Indications (3)
Worked on BENDAMUSTINE HYDROCHLORIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.